hotspot -WSS

hotspot

author：knowledge 2025-09-10 04:17:22 - browse：25865

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Scientists inch closer to single

leisure time

WSS

Sanders wants to replace patents with prizes for drug inventions

No plane should take off without an EpiPen onboard

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

NIH launches clinical trials and new research office for long Covid

There’s a way to spot data fakery. All journals should be using it

How a Boston hospital is priming medical residents to use GPT

focus

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Sanders wants to replace patents with prizes for drug inventions

Anesthesiologist group: stop taking Ozempic before surgery

NIH launches clinical trials and new research office for long Covid

After affirmative action ruling, medical educators look to 'holistic review'

Hormonal contraceptives don’t actually treat endometriosis

As demand for Covid shots wanes, Moderna seeks its next success

'CMA Fest' 2023: How to watch, who is performing and more

Wildfire smoke exposes gaps in outdoor worker protections

No plane should take off without an EpiPen onboard

focus

New safety details link Apellis eye drug to rare cases of blindness

EQRx, failed developer of low

Sage hopes for a blockbuster in antidepressant now before FDA

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

In rare move, senator releases unverified FBI source report alleging Biden bribe

Scientists grapple with ethics of stem cell research

entertainment

leisure time

explore

entertainment